(Q37588484)

21 August 2017

1 reference

title

Next generation multifunctional angiotensin receptor blockers (English)

1 reference

21 August 2017

Theodore W Kurtz

1

1 reference

PubMed ID

19713966

21 August 2017

Uwe Klein

series ordinal

2

1 reference

21 August 2017

28 August 2009

1 reference

21 August 2017

Hypertension Research

1 reference

21 August 2017

32

1 reference

21 August 2017

10

1 reference

21 August 2017

826-834

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2009.135

21 August 2017

0 references

cites work

The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Angiotensin receptor blockers: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

ACE inhibitors in cardiovascular disease--unbeatable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

The metabolic syndrome in hypertension: European society of hypertension position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Designed multiple ligands. An emerging drug discovery paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Characterization of new PPARgamma agonists: analysis of telmisartan's structural components

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

21 January 2018

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Recent clinical trials with omapatrilat: new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Role of endothelin-1 in clinical hypertension: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Demystified. Nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Nitric oxide and its role in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design, Synthesis, and Biopharmacological Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT1 Receptor Blockers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Combination therapy for hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Thrombolytics for PE and right ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.135

7 January 2021

Identifiers

DOI

10.1038/HR.2009.135

1 reference

21 August 2017

1 reference

PubMed ID

19713966